At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Continued Paroxetine CR +2 moredrug
Likely dose
Paroxetine CR (continued dose unspecified) plus Quetiapine (dose unspecified)AI-extracted
Key inclusion· 3
- ✓Male and female outpatients aged 18-72
- ✓Primary diagnosis of generalized anxiety disorder
- ✓May continue stable benzodiazepines if symptomatic despite at least one month of stable dosing
Key exclusion· 11
- ✕Pregnant or lactating women, or women of childbearing potential not using acceptable contraception
- ✕Primary diagnosis of major depression, dysthymia, panic disorder, or social phobia
- ✕Current or history of bipolar disorder, schizophrenia, or other psychotic conditions
- ✕PTSD or OCD current within the past 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
In Brief
A Phase 4 clinical trial evaluating Continued Paroxetine CR, Quetiapine, and 1 other intervention for Anxiety Disorder. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
First PostedJun 2005
Primary CompletionFeb 2007
Study CompletionNov 2007
TodayJul 2026
First PostedJun 8, 2005
Enrollment StartFeb 1, 2004
Primary CompletionFeb 1, 2007
Study CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 21.1 years ago
Interventions
Continued Paroxetine CRdrug
Quetiapinedrug
Placebodrug